Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Registration Number
- NCT00021723
- Brief Summary
A multi-center, double-blind, placebo-controlled out-patient, safety, tolerability, and pilot efficacy study of intramuscular AN-1792 in patients with mild to moderate Alzheimer's disease.
- Detailed Description
The study will enroll approximately 375 patients with mild to moderate Alzheimer's disease at investigational sites in the United States and Europe. Patients will receive either AN-1792 or placebo, and they will be evaluated using standard clinical assessments of cognition and memory as well as experimental surrogate markers of Alzheimer's disease pathology. The goal of the study is to evaluate the clinical impact of eliciting an immune response (formation of antibodies) to the A-beta peptide in patients with Alzheimer's disease.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 375
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (9)
Pivotal Research Centers
🇺🇸Peoria, Arizona, United States
21st Century Neurology
🇺🇸Phoenix, Arizona, United States
Pharmacology Research Institute
🇺🇸Northridge, California, United States
UCSD Medical Center
🇺🇸La Jolla, California, United States
Baumel-Eisner Neuromedical Institute
🇺🇸Ft. Lauderdale, Florida, United States
California Clinical Trials
🇺🇸Beverly Hills, California, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Clinical Pharmaceutical Trials, Inc.
🇺🇸Tulsa, Oklahoma, United States
Baylor College of Medicine
🇺🇸Houston, Texas, United States